FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280638082> ?p ?o ?g. }

• W4280638082 endingPage "154140" @default.
• W4280638082 startingPage "154140" @default.
• W4280638082 abstract "Rheumatoid arthritis (RA) is a long-term, progressive, and disabling autoimmune disease. It causes inflammation, swelling and pain in and around the joints and other body organs. Currently, no cure is available for RA. Clinical interventions can only relieve the condition, and at least 30% of RA patients do not respond to first‑line therapy. This means that the development of more effective therapies against RA is urgently needed. This study aimed to assess the anti-rheumatoid arthritis effect of chelerythrine (CLT) and explore its mechanism of action. The cytotoxic effect of CLT on human rheumatoid arthritis fibroblast-like synoviocyte (HFLS-RA) cells and HFLS-normal cells were measured by MTT assay. The growth and migration of HFLS-RA cells were determined by colony-formation and wound-healing assay. The level of intracellular reactive oxygen species (ROS) was detected using the DCFH-DA reagent. Cell apoptosis was measured by flow cytometry, TUNEL staining, caspase 3 activity, as well as the activation of apoptosis related proteins. In addition, the levels of autophagy related markers such as LC3B and P62 were determined by immunocytochemistry and western blotting. Lastly, the anti-RA effect of CLT was evaluated in an Adjuvant-Induced Arthritis(AIA) rat model and the severity of arthritis was detected and quantified using macroscopic inspection and X‑ray imaging. We discovered that treatment with CLT effectively inhibited the migration and colony-formation of the HFLS-RA cells and resulted in cell death. Moreover, CLT increased the intracellular level of ROS and the apoptotic rate of HFLS-RA by activating the AMPK/mTOR/ULK-1 signaling pathways. In vivo study showed CLT effectively ameliorated AIA in rats, protecting them from inflammation and bone damage. Our study shows CLT is an effective agent for ameliorating RA in vitro and in vivo by modulation of the AMPK/mTOR/ULK-1 signaling pathway. These findings indicate that CLT is a great potential candidate for development as a therapeutic agent for the prevention and treatment of RA." @default.
• W4280638082 created "2022-05-22" @default.
• W4280638082 creator A5008170761 @default.
• W4280638082 creator A5018785079 @default.
• W4280638082 creator A5056446518 @default.
• W4280638082 creator A5065615211 @default.
• W4280638082 creator A5066590728 @default.
• W4280638082 creator A5072433757 @default.
• W4280638082 creator A5078135227 @default.
• W4280638082 creator A5085530534 @default.
• W4280638082 date "2022-09-01" @default.
• W4280638082 modified "2023-10-18" @default.
• W4280638082 title "Chelerythrine ameliorates rheumatoid arthritis by modulating the AMPK/mTOR/ULK-1 signaling pathway" @default.
• W4280638082 cites W1817799409 @default.
• W4280638082 cites W1970637701 @default.
• W4280638082 cites W2000468514 @default.
• W4280638082 cites W2003409953 @default.
• W4280638082 cites W2011661614 @default.
• W4280638082 cites W2028536701 @default.
• W4280638082 cites W2044874695 @default.
• W4280638082 cites W2076357723 @default.
• W4280638082 cites W2087050539 @default.
• W4280638082 cites W2093014246 @default.
• W4280638082 cites W2098776090 @default.
• W4280638082 cites W2346868530 @default.
• W4280638082 cites W2566839077 @default.
• W4280638082 cites W2576602781 @default.
• W4280638082 cites W2622000437 @default.
• W4280638082 cites W2735199687 @default.
• W4280638082 cites W2788914874 @default.
• W4280638082 cites W2794384361 @default.
• W4280638082 cites W2795449839 @default.
• W4280638082 cites W2802434259 @default.
• W4280638082 cites W2803973097 @default.
• W4280638082 cites W2806969727 @default.
• W4280638082 cites W2808959429 @default.
• W4280638082 cites W2884010813 @default.
• W4280638082 cites W2890696535 @default.
• W4280638082 cites W2915931316 @default.
• W4280638082 cites W2974681108 @default.
• W4280638082 cites W2979052676 @default.
• W4280638082 cites W2989917244 @default.
• W4280638082 cites W3023489158 @default.
• W4280638082 cites W3047721739 @default.
• W4280638082 cites W3086998351 @default.
• W4280638082 cites W3092966039 @default.
• W4280638082 cites W3112343171 @default.
• W4280638082 doi "https://doi.org/10.1016/j.phymed.2022.154140" @default.
• W4280638082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35752081" @default.
• W4280638082 hasPublicationYear "2022" @default.
• W4280638082 type Work @default.
• W4280638082 citedByCount "4" @default.
• W4280638082 countsByYear W42806380822022 @default.
• W4280638082 countsByYear W42806380822023 @default.
• W4280638082 crossrefType "journal-article" @default.
• W4280638082 hasAuthorship W4280638082A5008170761 @default.
• W4280638082 hasAuthorship W4280638082A5018785079 @default.
• W4280638082 hasAuthorship W4280638082A5056446518 @default.
• W4280638082 hasAuthorship W4280638082A5065615211 @default.
• W4280638082 hasAuthorship W4280638082A5066590728 @default.
• W4280638082 hasAuthorship W4280638082A5072433757 @default.
• W4280638082 hasAuthorship W4280638082A5078135227 @default.
• W4280638082 hasAuthorship W4280638082A5085530534 @default.
• W4280638082 hasConcept C185592680 @default.
• W4280638082 hasConcept C190283241 @default.
• W4280638082 hasConcept C196795494 @default.
• W4280638082 hasConcept C203014093 @default.
• W4280638082 hasConcept C204232928 @default.
• W4280638082 hasConcept C2777077863 @default.
• W4280638082 hasConcept C2777575956 @default.
• W4280638082 hasConcept C31573885 @default.
• W4280638082 hasConcept C502942594 @default.
• W4280638082 hasConcept C55493867 @default.
• W4280638082 hasConcept C71924100 @default.
• W4280638082 hasConcept C86554907 @default.
• W4280638082 hasConcept C98274493 @default.
• W4280638082 hasConceptScore W4280638082C185592680 @default.
• W4280638082 hasConceptScore W4280638082C190283241 @default.
• W4280638082 hasConceptScore W4280638082C196795494 @default.
• W4280638082 hasConceptScore W4280638082C203014093 @default.
• W4280638082 hasConceptScore W4280638082C204232928 @default.
• W4280638082 hasConceptScore W4280638082C2777077863 @default.
• W4280638082 hasConceptScore W4280638082C2777575956 @default.
• W4280638082 hasConceptScore W4280638082C31573885 @default.
• W4280638082 hasConceptScore W4280638082C502942594 @default.
• W4280638082 hasConceptScore W4280638082C55493867 @default.
• W4280638082 hasConceptScore W4280638082C71924100 @default.
• W4280638082 hasConceptScore W4280638082C86554907 @default.
• W4280638082 hasConceptScore W4280638082C98274493 @default.
• W4280638082 hasFunder F4320323893 @default.
• W4280638082 hasFunder F4320326962 @default.
• W4280638082 hasLocation W42806380821 @default.
• W4280638082 hasLocation W42806380822 @default.
• W4280638082 hasOpenAccess W4280638082 @default.
• W4280638082 hasPrimaryLocation W42806380821 @default.
• W4280638082 hasRelatedWork W1500853876 @default.
• W4280638082 hasRelatedWork W1618068833 @default.
• W4280638082 hasRelatedWork W1987693880 @default.

• next